Remove 2028 Remove Dosage Remove Drug Development
article thumbnail

Responsible sourcing and manufacturing: Growing towards a sustainable future with Lonza

Express Pharma

As environmental concerns continue to intensify, the pressure on the pharmaceutical industry to reduce its overall environmental impact, particularly in final dosage forms, is growing proportionately. Lonzas comprehensive sustainability approach spans the entire value chain, from raw material selection to end-of-life solutions.

Dosage 104
article thumbnail

PROTAC development gains momentum, but clinical performance is poor

Pharmaceutical Technology

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. Both degraders, ARV-110 (bavdegalutamide) and ARV-766, are being developed by Arvinas.

Dosage 59